You are not logged in.

Ethical aspects of medical products of human origin

Martin, Dominique 2017, Ethical aspects of medical products of human origin, ISBT science series, vol. 12, no. 1, pp. 281-287, doi: 10.1111/voxs.12304.

Attached Files
Name Description MIMEType Size Downloads

Title Ethical aspects of medical products of human origin
Author(s) Martin, DominiqueORCID iD for Martin, Dominique orcid.org/0000-0001-9363-0770
Journal name ISBT science series
Volume number 12
Issue number 1
Start page 281
End page 287
Total pages 7
Publisher Wiley
Place of publication London, Eng.
Publication date 2017-02
ISSN 1751-2824
Keyword(s) bioethics
blood donation
organ donation
Summary Medical products of human origin (MPHOs) are ‘substances derived wholly or in part from human biological materials and intended for clinical application’. In 2014, the World Health Organization launched an Initiative for MPHOs. One of the primary goals of this Initiative is to establish global consensus on core principles that should guide policies and practices involving MPHO, particularly with regard to the procurement, distribution and use of these products. Like any medical products with therapeutic value for humans, the sufficiency of their supply, risks and benefits for recipients and equity in their allocation present ethical concerns for health policymakers, professionals and patients. Unlike other medical products, however, MPHOs present additional ethical concerns because their source materials are procured from living or deceased human beings. The clinical and psychosocial risks and benefits of donating specific materials for use in MPHOs vary according to characteristics of the donor, the material procured and the procurement process used. Risks and benefits, for example, continue to evolve as new procurement technologies, standards of donor care, and new donor populations emerge. Nevertheless, several core ethical concerns remain constant, distinguishing MPHOs as ‘exceptional’ health products. They include concerns about care of donors, inequities in donation and commercialization of ‘donation’ and MPHOs. In this article, I explore some major donor-related ethical concerns and argue that these provide a rationale for seeking to establish global consensus on ethical governance of all MPHOs, and a foundation for consensus on issues of donor care, and equity in donation and allocation of these exceptional health products.
Notes Special Issue: 34th International Congress of the International Society of Blood Transfusion, Dubai, United Arab Emirates, September 3–8, 2016
Language eng
DOI 10.1111/voxs.12304
Field of Research 220106 Medical Ethics
1103 Clinical Sciences
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2016, International Society of Blood Transfusion
Persistent URL http://hdl.handle.net/10536/DRO/DU:30088791

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 54 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Mon, 14 Nov 2016, 08:26:41 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.